Abstract
Objectives: Our objective was to compare the effectiveness of Traditional Chinese herbal Kampo medicine Goreisan in improving recurrence in patients with chronic subdural hematoma (CSDH).
Methods: Eligible randomized controlled trials prospective trials, and retrospective cohort studies were systematically identified through searches of PubMed, Cochrane Library, and CNKI from inception to March 2024. Following the application of predetermined inclusion and exclusion criteria to screen the available studies, main outcome measures were rigorously extracted. RevMan v5.4 software was utilized to evaluate the overall recurrence rate, employing a random-effects model to calculate pooled odds ratios with the Mantel-Haenszel estimation method. Inter-study heterogeneity was assessed using the Cochran Q (Chi-square) test and I2 statistics. Funnel plots were used to evaluate publication bias.
Results: Among the 48 articles initially screened for citation, eight were ultimately selected for inclusion in the study. The results of our network meta-analysis indicate that patients with newly diagnosed Chronic subdural hematoma experienced a significantly reduced recurrence rate when treated with Goreisan compared to standard neurosurgical treatment (OR: 0.72; 95% CI 0.61–0.86; p = 0.00003). There was no statistically significant difference in the incidence rates of complications, including general fatigue, allergic reactions, hepatic dysfunction, and interstitial pneumonia (OR: 7.21; 95% CI 0.37–141.29; p = 0.19).
Conclusion: Traditional medicine Goreisan was effective in reducing CDSH recurrence rates. For clinical treatment, it provides a high level of evidence-based medicine. It is also necessary to conduct multicenter randomized controlled trials with dose adjustments to determine whether Goreisan interventions improve neurological function or prognosis.
Introduction
Chronic subdural hematoma (CSDH) is a common neurological disease, It is reported that 20.6 out of every 100,000 people suffer from chronic diseases annually (Yu et al., 2022). The aging global population is anticipated to contribute to a rise in the prevalence of CSDH cases (Balser et al., 2015). In elderly patients, the presence of enlarged subdural spaces is often linked to the use of oral anticoagulants and cerebral atrophy. CSDH typically occurs following minor trauma, leading to the accumulation of blood between the dura and arachnoid membranes (Yasunaga, 2015).
The burr-hole craniotomy is the standard treatment for CSDH, although studies indicate that recurrence rates can range from 4% to 30% and that it is associated with a poor outcome (Hutchinson et al., 2024). Prevailing theories implicating angiogenesis, inflammation and hyperfibrinolysis are the mechanisms behind reoccurrence (Edlmann et al., 2017; Wu et al., 2023). Based on these theories, Inflammation, angiogenesis and hyperfibrinolysis have been targeted with treatments (Huang et al., 2020; Desir et al., 2023). Nonetheless, recurrence rates remain disconcertingly high, necessitating the discovery of novel treatment targets.
Currently, western medicine dominates drug research for chronic subdural hematomas, whereas traditional medicine is rarely explored. As a traditional herbal Kampo medicine, Goreisan consists of five herbs (Alismatis rhizoma, Atractylodis rhizoma, Polyporus, Poria, and Cinnamomi cortex) (Goto et al., 2018), It has been recently reported that Goreisan acts on aquaporins (AQPs), specifically AQP1/4, and can be used to treat asymptomatic CSDH and prevent its recurrence after surgery (Yano et al., 2017; Harada et al., 2020). However, most of the previous clinical studies on Goreisan’s use to treat CSDH were published in Japanese journals and were small case series. It is therefore controversial whether Goreisan is effective in treating CSDH. And a high level of evidence-based medicine is urgently needed.
Until now, no conventional meta-analysis has investigated the effectiveness of Goreisan as a treatment for CSDH recurrence. This is the first meta-analysis that shows Goreisan’s effectiveness as a treatment for CSDH recurrence.
Materials and methods
Meta-analysis
PubMed, Cochrane libraries, and CNKI provide broad access to literature, regardless of year or language, when conducting reviews. A combination of Medical Subject Headings (MeSH) and search terms were used with Boolean logical operators, such as “Chronic subdural hematoma,” “Goreisan,” “Prospective cohort studies,” “Randomized controlled trials,” “Retrospective cohort studies,” and other relevant synonyms.
Selection criteria
We evaluated all eligible citations and excluded those that failed to meet inclusion criteria or were repeated. We read the full text carefully to further evaluate the article’s relevance. Further exploration of relevant research is conducted by analyzing references in the included articles. All references are processed in Endnote X9 (Research Soft, Philadelphia, United States).
Inclusion and exclusion criteria
Inclusion criteria included: 1) Chronic Subdural Hematoma was diagnosed by all enrolled patients; 2) Comparative studies should be randomized controlled trials or prospective studies or retrospective; 3) Each study should include at least 30 patients. 4) report key outcome indicators. Specifically, patients with Chronic Subdural Hematoma and those under the age of 18 were excluded. Recurrence rate was the primary outcome measure for patients with Chronic Subdural Hematoma. A secondary outcome was complications associated with the Chinese Traditional medicine Goreisan. In the study, recurrence was defined as a new symptomatic Chronic Subdural Hematoma occurring during the study period.
Data extraction and quality assessment
A study was carried out by three authors (Zhenyu Yang, Yuecheng Zen, and Jinyang Hu) independently to extract and summarize data eligible for inclusion and exclusion standards. Demographic characteristics and data were analyzed for all articles that were included in the review. To create baseline data for this study, we extracted relevant information such as the title of the study, the author, the year of publication, the country, region, and basic characteristics. Review Manager (Version 5.4), a tool for evaluating bias in included studies, was used to assess study quality.
Statistical analyses
The overall recurrence rate was evaluated using RevMan v5.4. Pooled odds ratios were assessed using a random-effects model and the Mantel-Haenszel estimation method. To evaluate the heterogeneity between the studies, Cochran’s Q test (Chi-square) was used, as were I2 statistics. An I2 value of more than 50% was considered moderate heterogeneity, and significance was determined using 95% confidence intervals or p < 0.05 (Higgins et al., 2003).
Results
Patient characteristics and study identification
In the initial screening of 48 pieces of literature, Afterfull-text examination of the remaining articles, 15 articles were included, as seven articles were not RCTs, prospective or retrospective studies, eight were ultimately included after further screening. A flow chart illustrating the process of document selection is shown in Figure 1. The studies included in this study were published from 2013 to 2024. In Figure 2, we summarize the main characteristics and pharmacological interventions of the eight trials that were included. The patients in each study had CSDH. Three articles were RCTs, and one article was prospective studies, four articles were retrospective. Treatment time varied from 1 to 12 weeks, all patients included in the literature underwent trepanation and drainage of subdural hematoma. A summary of the main data from the included trials is presented in Figure 3. Overall, all trials reported recurrence rates; in the intervention group, the rate was 9.75% (range: 5%–30.9%) and in the control group, it was 15.2% (range: 6.2%–29%).
FIGURE 1
FIGURE 2
FIGURE 3
Risk of bias quality assessment
Four of the eight trials included were described in detail as Random sequence generation with low risk. In two studies, blinding of outcomes assessment resulted in unclear risk, which could have led to detection bias. Incomplete outcome data led to five studies being rated as high risk or unclear risk. Figures 4, 5 summarize bias at the individual and population levels.
FIGURE 4
FIGURE 5
Details of the surgical procedure
This paper provides a comprehensive overview of the methodology involved in performing trepanation and drainage for chronic subdural hematoma. The selection of anesthesia is a crucial initial step following the decision to proceed with surgery. Following preoperative imaging analysis, the scalp and subcutaneous tissue are incised at the thickest point of the hematoma, with subsequent drilling of the dura. Post-drilling, a drainage tube is promptly inserted and secured with subcutaneous sutures. The hematoma cavity was irrigated with warm saline solution until the effluent was predominantly cleared, followed by the attachment of the external drainage bag to the drainage tube (Hwang et al., 2022; Uno, 2023).
Meta-analysis for recurrence rate and secondary outcomes
When Goreisan was used in conjunction with standard neurosurgical treatment to treat newly diagnosed chronic subdural hematomas, the recurrence rate was significantly lower than with standard neurosurgical treatment alone (OR: 0.72; 95% CI 0.61–0.86; p = 0.00003). A low level of heterogeneity was found among studies (I2 = 7.31%, p = 0.40) shown in Figure 6. Inverted funnel plots reveal little asymmetric scattering points, indicating little publication bias shown in Figure 7. Complications (general fatigue, allergic reaction, hepatic dysfunction, and interstitial pneumonia) rates were not significantly different (OR: 7.21; 95% CI 0.37–141.29; p = 0.19) Figure 8.
FIGURE 6
FIGURE 7
FIGURE 8
Discussion
Globally, CSDH incidence and societal impact are predicted to increase as the population ages and anticoagulants become more prevalent, posing an increasing public health threat (Kolias et al., 2014). There is an ongoing debate about the definitive management of chronic subdural hematomas. Although surgical intervention remains the only established treatment option, it is associated with substantial recurrence and mortality rates, estimated at 5%–33%, especially among older and frail patients, increasing morbidity and mortality as well as prolonging hospital stays (Matsumoto et al., 2024).
Numerous studies have indicated that the presence of inflammatory factors and chemokines plays a major role in the development of CSDH and enlargement of the hematoma (de Oliveira et al., 2022; Fan et al., 2022). There is also evidence that high levels of VEGF enhance microangiogenesis and vascular permeability (Edlmann et al., 2022; Petrov et al., 2022). Additionally, the activation of plasminase in CSDH hematomas leads to a significant increase in thrombosis regulatory protein and high fibrinolysis, which promotes blood vessel leakage leading to CSDH progression (Katano et al., 2006; Matsubara et al., 2023). As a result of the understanding that inflammation, angiogenesis, and hyperfibrinolysis play a role in the development of CSDH, there have been several adjunctive therapies used to help reduce recurrence rates, including steroids, angiotensin-converting enzyme inhibitors, tranexamic acid, etizolam, and atorvastatin (Jiang et al., 2018; Tamura et al., 2021). Despite this, there is no consensus on the best adjuvant treatment, and the recurrence rate is still high, necessitating the discovery of novel treatment targets.
AQPs exist in cell membranes and play a key role in maintaining homeostasis and cell migration (Castle, 2005), considered to be a factor affecting the growth of CSDH (Goto et al., 2018), especially AQP1 and AQP4 (Basaldella et al., 2010; Yano et al., 2017). The possible factor leading to the recurrence of CSDH is AQP1 which affects the angiogenesis of the outer membrane (Basaldella et al., 2010). In the central nervous system, aquaporin-4 plays a critical role in increasing membrane permeability to water, which expressed in the outer membrane, especially in areas typically invaded by inflammatory cells, leads to hematoma formation and expansion (Okamura et al., 2013). Several studies have shown that Goreisan could inhibit AQP1 and AQP4 expression and function (Yasunaga, 2015; Yamada and Natori, 2020). This is also a potential mechanism by which Goreisan can reduce the recurrence rate of CDSH. However, the efficacy of Goreisan for CSDH is subject to some controversy in the real world (Okamura et al., 2013; Goto et al., 2018; Katayama et al., 2018; Harada et al., 2020; Yamada and Natori, 2020; Fujisawa et al., 2021; Matsumoto et al., 2024). So, there is an urgent need for high-quality evidence-based medical evidence.
No previous meta-analysis has examined Goreisan’s effect on recurrences of CSDH. Our results suggest that Goreisan can significantly reduce the recurrence rate of CDSH (OR: 0.72; 95% CI 0.61–0.86; p = 0.00003), and improve the quality life of patients. Complication (general fatigue, allergic reaction, hepatic dysfunction, and interstitial pneumonia) rates were not significantly different (OR: 7.21; 95% CI 0.37–141.29; p = 0.19). However, there are some drawbacks to our study. A major limitation of our study is the lack of randomized controlled trials or prospective studies on Goreisan interventions, and all included studies were in Japanese populations, limiting the evidence on their efficacy and generalisability. In addition, some trials were of low quality, which could potentially undermine the validity of our analysis. It will still be necessary to conduct multicenter, randomized controlled trials to evaluate Goreisan on its own or in combination with other interventions in order to determine if it improves neurological function or prognosis in the future.
Conclusion
As a result of our findings, Traditional medicine Goreisan was effective in reducing CDSH recurrence rates. For clinical treatment, it provides a high level of evidence-based medicine. It is also necessary to conduct multicenter randomized controlled trials with dose adjustments to determine whether Goreisan interventions improve neurological function or prognosis.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Author contributions
ZY: Writing–original draft, Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing–review and editing. YZ: Writing–original draft, Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing–review and editing. JH: Writing–review and editing, Writing–original draft. XH: Data curation, Software, Writing–review and editing. YL: Formal Analysis, Project administration, Supervision, Writing–review and editing. HZ: Formal Analysis, Project administration, Supervision, Writing–review and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the medical health research project of Yichang (A23-1-038).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
BalserD.FarooqS.MehmoodT.ReyesM.SamadaniU. (2015). Actual and projected incidence rates for chronic subdural hematomas in United States Veterans Administration and civilian populations. J. Neurosurg.123, 1209–1215. 10.3171/2014.9.JNS141550
2
BasaldellaL.PerinA.OrvietoE.MartonE.ItskevichD.Dei TosA. P.et al (2010). A preliminary study of aquaporin 1 immunolocalization in chronic subdural hematoma membranes. J. Clin. Neurosci.17, 905–907. 10.1016/j.jocn.2009.11.010
3
CastleN. A. (2005). Aquaporins as targets for drug discovery. Drug Discov. today10, 485–493. 10.1016/S1359-6446(05)03390-8
4
de OliveiraA. J. M.SollaD. J. F.de OliveiraK. F.AmaralB. S.AndradeA. F.KoliasA. G.et al (2022). Postoperative neutrophil-to-lymphocyte ratio variation is associated with chronic subdural hematoma recurrence. Neurol. Sci.43, 427–434. 10.1007/s10072-021-05241-y
5
DesirL. L.NarayanV.EllisJ.GordonD.LangerD.OrtizR.et al (2023). Middle meningeal artery embolization in the management of chronic subdural hematoma: a comprehensive review of current literature. Curr. neurology Neurosci. Rep.23, 109–119. 10.1007/s11910-023-01262-6
6
EdlmannE.Giorgi-CollS.ThelinE. P.HutchinsonP. J.CarpenterK. L. H. (2022). Dexamethasone reduces vascular endothelial growth factor in comparison to placebo in post-operative chronic subdural hematoma samples: a target for future drug therapy?Front. neurology13, 952308. 10.3389/fneur.2022.952308
7
EdlmannE.Giorgi-CollS.WhitfieldP. C.CarpenterK. L. H.HutchinsonP. J. (2017). Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy. J. neuroinflammation14, 108. 10.1186/s12974-017-0881-y
8
FanY.WuD.ZhangX.JiangW.NieM.LiuX.et al (2022). The inflammatory cellular feature in the peripheral blood of chronic subdural hematoma patients. J. Clin. laboratory analysis36, e24706. 10.1002/jcla.24706
9
FujisawaN.OyaS.YoshidaS.TsuchiyaT.NakamuraT.IndoM.et al (2021). A prospective randomized study on the preventive effect of Japanese herbal Kampo medicine goreisan for recurrence of chronic subdural hematoma. Neurol. medico-chirurgica61, 12–20. 10.2176/nmc.oa.2020-0287
10
GotoS.KatoK.YamamotoT.ShimatoS.OhshimaT.NishizawaT. (2018). Effectiveness of goreisan in preventing recurrence of chronic subdural hematoma. Asian J. Neurosurg.13, 370–374. 10.4103/ajns.AJNS_174_16
11
HaradaY.YoshidaK.NojiriS.KuriharaY.KobayashiH.AraiH. (2020). Identification of chronic subdural hematoma types most responsive to Goreisan, Kampo medicine: a retrospective study. J. Clin. Neurosci.78, 198–202. 10.1016/j.jocn.2020.04.063
12
HigginsJ. P.ThompsonS. G.DeeksJ. J.AltmanD. G. (2003). Measuring inconsistency in meta-analyses. BMJ327, 557–560. 10.1136/bmj.327.7414.557
13
HuangJ.GaoC.DongJ.ZhangJ.JiangR. (2020). Drug treatment of chronic subdural hematoma. Expert Opin. Pharmacother.21, 435–444. 10.1080/14656566.2020.1713095
14
HutchinsonP. J.EdlmannE.HanrahanJ. G.BultersD.ZolnourianA.HoltonP.et al (2024). A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial). Health Technol. Assess. Winch. Engl.28, 1–122. 10.3310/XWZN4832
15
HwangY.ChoiS.KimY. S.ParkJ. S.ChoiJ. H.JeunS. S.et al (2022). Comparative analysis of safety and efficacy in subperiosteal versus subdural drainage after burr-hole trephination for chronic subdural hematoma. Clin. neurology Neurosurg.212, 107068. 10.1016/j.clineuro.2021.107068
16
JiangR.ZhaoS.WangR.FengH.ZhangJ.LiX.et al (2018). Safety and efficacy of atorvastatin for chronic subdural hematoma in Chinese patients: a randomized ClinicalTrial. JAMA neurol.75, 1338–1346. 10.1001/jamaneurol.2018.2030
17
KatanoH.KamiyaK.MaseM.TanikawaM.YamadaK. (2006). Tissue plasminogen activator in chronic subdural hematomas as a predictor of recurrence. J. Neurosurg.104, 79–84. 10.3171/jns.2006.104.1.79
18
KatayamaK.MatsudaN.KakutaK.NaraokaM.TakemuraA.HasegawaS.et al (2018). The effect of goreisan on the prevention of chronic subdural hematoma recurrence: multi-center randomized controlled study. J. neurotrauma35, 1537–1542. 10.1089/neu.2017.5407
19
KoliasA. G.ChariA.SantariusT.HutchinsonP. J. (2014). Chronic subdural haematoma: modern management and emerging therapies. Nat. Rev. Neurol.10, 570–578. 10.1038/nrneurol.2014.163
20
MatsubaraM.YagiK.MinamiY.KandaE.SunadaY.TaoY.et al (2023). Preoperative elevated eosinophils in peripheral blood for prediction of postoperative recurrence of chronic subdural hematoma. J. Neurosurg.139, 708–713. 10.3171/2022.12.JNS222432
21
MatsumotoH.MatsumotoA.MiyataS.TomoganeY.MinamiH.MasudaA.et al (2024). The effect of Japanese herbal medicines (Kampo) goreisan and saireito on the prevention of recurrent chronic subdural hematoma: a prospective randomized study. Neurosurgery94, 80–89. 10.1227/neu.0000000000002649
22
OkamuraA.KawamotoY.SakodaE.MurakamiT.HaraT. (2013). Evaluation of recurrence factors and Gorei-san administration for chronic subdural hematoma after percutaneous subdural tapping. Hiroshima J. Med. Sci.62, 77–82.
23
PetrovA.IvanovA.DryaginaN.PetrovaA.SamochernykhK.RozhchenkoL. (2022). Angiogenetic factors in chronic subdural hematoma development. Diagn. (Basel)12, 2787. 10.3390/diagnostics12112787
24
TamuraR.SatoM.YoshidaK.TodaM. (2021). History and current progress of chronic subdural hematoma. J. neurological Sci.429, 118066. 10.1016/j.jns.2021.118066
25
UnoM. (2023). Chronic subdural hematoma-evolution of etiology and surgical treatment. Neurol. medico-chirurgica63, 1–8. 10.2176/jns-nmc.2022-0207
26
WuZ.WangH.ZhaoJ.WangC.LiuH.WangC.et al (2023). Preoperative fibrinogen levels and function as predictive factors for acute bleeding in the hematoma cavity after burr hole drainage in patients with CSDH. World Neurosurg.180, e364–e375. 10.1016/j.wneu.2023.09.072
27
YamadaT.NatoriY. (2020). Prospective study on the efficacy of orally administered tranexamic acid and goreisan for the prevention of recurrence after chronic subdural hematoma burr hole surgery. World Neurosurg.134, e549–e553. 10.1016/j.wneu.2019.10.134
28
YanoY.YanoH.TakahashiH.YoshimotoK.TsudaS.FujiyamaK.et al (2017). Goreisan inhibits upregulation of aquaporin 4 and formation of cerebral edema in the rat model of juvenile hypoxic-ischemic encephalopathy. Evidence-based complementary Altern. Med.2017, 3209219. 10.1155/2017/3209219
29
YasunagaH. (2015). Effect of Japanese herbal Kampo medicine goreisan on reoperation rates after burr-hole surgery for chronic subdural hematoma: analysis of a national inpatient database. Evidence-based complementary Altern. Med.2015, 817616. 10.1155/2015/817616
30
YuW.ChenW.JiangY.MaM.ZhangW.ZhangX.et al (2022). Effectiveness comparisons of drug therapy on chronic subdural hematoma recurrence: a bayesian network meta-analysis and systematic review. Front. Pharmacol.13, 845386. 10.3389/fphar.2022.845386
Summary
Keywords
Goreisan, traditional herbal Kampo medicine, chronic subdural hematoma, recurrence, meta-analysis
Citation
Yang Z, Zeng Y, Hu J, Huang X, Zhang H and Liu Y (2024) Effectiveness of traditional herbal Kampo medicine Goreisan on chronic subdural hematoma recurrence: a meta-analysis. Front. Pharmacol. 15:1412190. doi: 10.3389/fphar.2024.1412190
Received
09 April 2024
Accepted
19 June 2024
Published
15 July 2024
Volume
15 - 2024
Edited by
Javier Echeverria, University of Santiago, Chile
Reviewed by
Jessian Munoz, Texas Children’s Hospital, United States
Hiroki Sato, Saitama Medical University International Medical Center, Japan
Updates
Copyright
© 2024 Yang, Zeng, Hu, Huang, Zhang and Liu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Haiquan Zhang, dusihai24@163.com; Yang Liu, yangliuat@yeah.net
†These authors share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.